NYSE:BSX - New York Stock Exchange, Inc. - US1011371077 - Common Stock - Currency: USD
BOSTON SCIENTIFIC CORP
NYSE:BSX (1/27/2025, 11:47:10 AM)
101.1
-0.84 (-0.82%)
The current stock price of BSX is 101.1 USD. In the past month the price increased by 13.44%. In the past year, price increased by 66.76%.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
In-Depth Technical Analysis of BOSTON SCIENTIFIC CORP.
/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSEâ„¢ Pulsed Field Ablation (PFA) System* and the...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.6 | 223.53B | ||
ISRG | INTUITIVE SURGICAL INC | 78.11 | 203.94B | ||
SYK | STRYKER CORP | 34.08 | 151.22B | ||
MDT | MEDTRONIC PLC | 17.42 | 117.29B | ||
BDX | BECTON DICKINSON AND CO | 18.75 | 71.55B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 21.08 | 40.64B | ||
EW | EDWARDS LIFESCIENCES CORP | 25.69 | 40.45B | ||
RMD | RESMED INC | 31.02 | 37.75B | ||
IDXX | IDEXX LABORATORIES INC | 38.84 | 34.82B | ||
DXCM | DEXCOM INC | 51.86 | 34.43B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.16 | 25.58B | ||
ZBH | ZIMMER BIOMET HOLDINGS INC | 14.12 | 22.18B |
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 48,000 full-time employees. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. The company also owns the transcarotid artery revascularization (TCAR) platform.
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752 US
CEO: Michael F. Mahoney
Employees: 48000
Company Website: https://www.bostonscientific.com/en-US/Home.html
Investor Relations: https://investors.bostonscientific.com
Phone: 15086834000
The current stock price of BSX is 101.1 USD.
The exchange symbol of BOSTON SCIENTIFIC CORP is BSX and it is listed on the New York Stock Exchange, Inc. exchange.
BSX stock is listed on the New York Stock Exchange, Inc. exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for BSX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of BSX.
BSX does not pay a dividend.
BSX will report earnings on 2025-02-05, after the market close.
The PE ratio for BSX is 42.84. This is based on the reported non-GAAP earnings per share of 2.36 and the current share price of 101.1 USD.
The outstanding short interest for BSX is 0.99% of its float.
ChartMill assigns a technical rating of 10 / 10 to BSX. When comparing the yearly performance of all stocks, BSX is one of the better performing stocks in the market, outperforming 90.69% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to BSX. BSX has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 2.36. The EPS increased by 18.59% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 11.27% | ||
ROA | 4.71% | ||
ROE | 8.66% | ||
Debt/Equity | 0.45 |
ChartMill assigns a Buy % Consensus number of 84% to BSX. The Buy consensus is the average rating of analysts ratings from 38 analysts.
For the next year, analysts expect an EPS growth of 21.26% and a revenue growth 17.63% for BSX